Metabolic control and cardiovascular risk factors in type 2 diabetes mellitus patients according to diabetes duration

Abstract

The degree of glycaemic control and the risk factors in relation to the duration of T2DM followed different patterns. Diabetes duration was associated with a poorer glycaemic control but in general had a limited role in blood pressure control or lipid profile.

Quality of diabetes care at the largest outpatient clinics in Vilnius

“…The estimated worsening of diabetes control with an increasing number of complications, disease duration and intensification of treatment, same as a worse glycaemic control in the patients treated with insulin compared to oral therapy users in the T2DM group, agrees with the previously published data (10, 12, 19). …”

“…Our data showed that 55.3% of patients achieved HbA1c < 7% which is worse than the average result in other European countries – 62.6%, reported in the Panorama study (22), but falls in between countries, where the percentage of T2DM patients reaching the target HbA1c ≤ 7 varies from 48.1 to 76.0% (10, 12, 19, 21, 23). …”

“…The average HbA1c in the T2DM was significantly better compared to that in the T1DM group – 7.0% vs 9.1%. The results of studies, conducted in T2DM subjects, showed an average HbA1c of 7.5% in Estonia, 6.8–7.2% in Spain, 6.7% in Germany, 7.0% in Greece, 7.1% in Belgium (9–12, 17, 19). Our study revealed a very poor glycaemic control in the T1DM which, however, is in line with the meta-analysis of the registers of 11 countries published by McKnight et al, where the median HbA1c in the T1DM varied from 7.4 to 9.4% (20).…”

Long-term safety of once-daily, dual-release hydrocortisone in patients with adrenal insufficiency: a phase 3b, open-label, extension study

“…The maintenance of stable blood pressure throughout the 5-year study is particularly noteworthy in the elderly and patients with DM who are more likely to have hypertension (31, 32) Indeed, age-dependent changes would likely become evident during this period in DM patients. For example, blood pressure may be expected to increase by approximately 1 mmHg (33, 34) and, in patients with type 2 diabetes, HbA1c has been shown to deteriorate by 0.5% per year (35). However, long-term trends should be interpreted with caution given that there was no control group, the number of subjects was small and changes in antidiabetic, antihypertensive and lipid-lowering medications were not recorded in this study.…”

Multidimensional effects of metformin in patients with type 2 diabetes

“…Длительность СД2 является одним из наиболее важ-ных показателей наличия осложнений СД, поскольку тесно связана со скоростью прогрессирования атеро-склероза [50], вновь акцентируя внимание на эффекте «метаболической памяти». И здесь важно понимать, что именно метформин обосновал целое направле-ние современной диабетологии: влияние сахаросни-жающей терапии не только путем контроля гликемии, но и за его пределами [6].…”